•
FU
FULC
Fulcrum Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
687.41M
Volume
876.16K
52W High
$15.74
52W Low
$2.32
Open
$0.00
Prev Close
$10.60
Day Range
0.00 - 0.00
About Fulcrum Therapeutics, Inc. Common Stock
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Latest News
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider
GlobeNewswire Inc.•Dec 12
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Benzinga•Dec 10
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
GlobeNewswire Inc.•Dec 6
Datanomix and Fulcrum Modernize Manufacturing Tech Stacks with Seamless ERP + Production Monitoring Integration
GlobeNewswire Inc.•Nov 19
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Oct 10
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Sep 12
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Feb 7
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
GlobeNewswire Inc.•Nov 6